ArriVent BioPharma Shares Rise 9.3% on Initial Cancer Trial Data
Shares gained 9.3% to $22.95 in premarket trading after ArriVent announced positive initial Phase 1 data for a gastrointestinal cancer treatment. The body is truncated after “The drug con”.